This, together with the low mutation rate in the members of the TGF-β canonical signalling pathway observed in iCCA patients, may counteract the positive effects of TGF-β inhibitors in boosting immunotherapies. Here, TGFB1 is linked to infantile convulsions and choreoathetosis.